Caisse DE Depot ET Placement DU Quebec lessened its position in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 24.9% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 30,354 shares of the biopharmaceutical company’s stock after selling 10,070 shares during the period. Caisse DE Depot ET Placement DU Quebec’s holdings in Alexion Pharmaceuticals were worth $3,630,000 at the end of the most recent reporting period.
Several other hedge funds have also recently added to or reduced their stakes in the company. Amundi Pioneer Asset Management Inc. increased its holdings in shares of Alexion Pharmaceuticals by 1,786.3% in the 4th quarter. Amundi Pioneer Asset Management Inc. now owns 1,454,498 shares of the biopharmaceutical company’s stock valued at $173,944,000 after purchasing an additional 1,377,388 shares in the last quarter. Investec Asset Management LTD purchased a new position in shares of Alexion Pharmaceuticals in the 4th quarter valued at about $84,096,000. Alkeon Capital Management LLC purchased a new position in shares of Alexion Pharmaceuticals in the 3rd quarter valued at about $70,145,000. Wells Fargo & Company MN increased its holdings in shares of Alexion Pharmaceuticals by 32.7% in the 3rd quarter. Wells Fargo & Company MN now owns 1,558,531 shares of the biopharmaceutical company’s stock valued at $218,647,000 after purchasing an additional 383,713 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership increased its holdings in shares of Alexion Pharmaceuticals by 1,010.4% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 310,900 shares of the biopharmaceutical company’s stock valued at $37,181,000 after purchasing an additional 282,900 shares in the last quarter. Institutional investors own 95.38% of the company’s stock.
A number of brokerages have recently issued reports on ALXN. Cowen reiterated a “buy” rating and issued a $163.00 price target on shares of Alexion Pharmaceuticals in a report on Friday. BMO Capital Markets increased their price target on shares of Alexion Pharmaceuticals from $177.00 to $180.00 and gave the company an “outperform” rating in a report on Friday, February 9th. Deutsche Bank set a $161.00 price target on shares of Alexion Pharmaceuticals and gave the company a “buy” rating in a report on Friday, February 9th. Stifel Nicolaus restated a “buy” rating and set a $151.00 target price on shares of Alexion Pharmaceuticals in a report on Friday, February 9th. Finally, ValuEngine downgraded shares of Alexion Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, March 1st. Three equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and twenty have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $154.64.
Shares of Alexion Pharmaceuticals, Inc. (ALXN) opened at $127.08 on Tuesday. The company has a market cap of $28,170.00, a PE ratio of 58.56, a PEG ratio of 1.16 and a beta of 1.13. Alexion Pharmaceuticals, Inc. has a twelve month low of $96.18 and a twelve month high of $149.34. The company has a current ratio of 3.10, a quick ratio of 2.62 and a debt-to-equity ratio of 0.34.
Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its quarterly earnings results on Thursday, February 8th. The biopharmaceutical company reported $1.48 EPS for the quarter, topping analysts’ consensus estimates of $1.09 by $0.39. The business had revenue of $909.70 million during the quarter, compared to the consensus estimate of $880.38 million. Alexion Pharmaceuticals had a net margin of 12.48% and a return on equity of 12.94%. The company’s quarterly revenue was up 9.5% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.26 earnings per share. research analysts predict that Alexion Pharmaceuticals, Inc. will post 6.12 EPS for the current year.
ILLEGAL ACTIVITY WARNING: This news story was originally posted by American Banking News and is owned by of American Banking News. If you are viewing this news story on another website, it was illegally stolen and republished in violation of US & international copyright & trademark legislation. The original version of this news story can be viewed at https://www.americanbankingnews.com/2018/03/13/alexion-pharmaceuticals-inc-alxn-stake-lowered-by-caisse-de-depot-et-placement-du-quebec.html.
Alexion Pharmaceuticals Profile
Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).
Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.